Bullboard Post History

by jimsenior

Order by:

T.ONC	RE:RE:RE:RE:RE:RE:It's on Twitter... ASCO Results @Noteable. Did you mean Confidence Interval? TIA June 4, 2023
T.ONC	RE:RE:RE:It's on Twitter... ASCO Results @lonc17. If you read Noteable's post at 10:14 today. you would... June 4, 2023
T.ONC	RE:It's on Twitter... ASCO Results @Dude1234 on STW. Search Phase 1 Trial of Sargramostim/Pelareorep. There is... June 3, 2023
T.ONC	RE:RE:RE:RE:RE:RE:RE:RE:RE:CAR-T Abstract from Mayo Clinic (Vile group) using pela Hello Henry, Let me introduce you to James P. Allison, 2018 Nobel Prize... June 2, 2023
T.ONC	RE:RE:RE:RE:RE:RE:RE:CAR-T Abstract from Mayo Clinic (Vile group) using pela Good Morning Capitalista, I refer you to a press release dated April 14... June 2, 2023
T.ONC	RE:RE:RE:RE:RE:RE:CAR-T Abstract from Mayo Clinic (Vile group) using pela @Noteable. An excellent solution. I shall resist trying to tilt the answer in... June 1, 2023
T.ONC	RE:RE:RE:RE:CAR-T Abstract from Mayo Clinic (Vile group) using pela @Noteable. We are both talking about the CAR T abstract at ASCO... June 1, 2023
T.ONC	RE:RE:RE:RE:CAR-T Abstract from Mayo Clinic (Vile group) using pela @Noteable. Yes a Good Thing; 100 per cent. I am just curious about a few... June 1, 2023
T.ONC	RE:RE:CAR-T Abstract from Mayo Clinic (Vile group) using pela Does this current abstract differ in that they used EGFRvIII CAR T cells? And... June 1, 2023
T.ONC	RE:RE:Share Price CAR T Thank you to the poster on STW., who posted the CAR T abstract. Very... June 1, 2023
T.ONC	RE:Share Price @venture009. Very well put. I was trying to think of something to say, and... June 1, 2023
T.ONC	RE:ONCY gears up for Phase 3 trial in HR+/HER2- breast cancer @Noteable. Thanks for pointing out this site. Well written piece. The use of... May 31, 2023
T.ONC	RE:RE:RE:RE:RE:RE:RE:Turning to Goblet To my Fellow Shareholders: One Marcus Antonius on yahoo has prophesied the... May 31, 2023
T.ONC	RE:RE:RE:RE:RE:RE:Turning to Goblet @Q. Thank you for allowing the possibility of synergy. I thought of it while... May 30, 2023
T.ONC	RE:RE:RE:RE:Turning to Goblet TIGIT is an immune inhibitory receptor and plays a key role in the... May 30, 2023
T.ONC	RE:RE:RE:Turning to Goblet GOBLET - On March 31, 2022. ONCY announced successful... May 30, 2023
T.ONC	RE:RE:RE:Drum beat until May 25th Spelling correction. Tecentriq. May 6, 2023
T.ONC	RE:RE:Drum beat until May 25th It has been suggested that mBC may be going forward without a CPI. As the... May 6, 2023
T.ONC	RE:Drum beat until May 25th @SundayMovies. I found some valuable info at the following search. ... May 5, 2023
T.ONC	RE:News tomorrow (surprise news) That is the fourth funniest post I have seen on this board: behind Noteable... May 4, 2023

Become a member today, It's free!

Bullboard Post History

by jimsenior

RE:RE:RE:RE:RE:RE:It's on Twitter... ASCO Results

RE:RE:RE:It's on Twitter... ASCO Results

RE:It's on Twitter... ASCO Results

RE:RE:RE:RE:RE:RE:RE:RE:RE:CAR-T Abstract from Mayo Clinic (Vile group) using pela

RE:RE:RE:RE:RE:RE:RE:CAR-T Abstract from Mayo Clinic (Vile group) using pela

RE:RE:RE:RE:RE:RE:CAR-T Abstract from Mayo Clinic (Vile group) using pela

RE:RE:RE:RE:CAR-T Abstract from Mayo Clinic (Vile group) using pela

RE:RE:RE:RE:CAR-T Abstract from Mayo Clinic (Vile group) using pela

RE:RE:CAR-T Abstract from Mayo Clinic (Vile group) using pela

RE:RE:Share Price

RE:Share Price

RE:ONCY gears up for Phase 3 trial in HR+/HER2- breast cancer

RE:RE:RE:RE:RE:RE:RE:Turning to Goblet

RE:RE:RE:RE:RE:RE:Turning to Goblet

RE:RE:RE:RE:Turning to Goblet

RE:RE:RE:Turning to Goblet

RE:RE:RE:Drum beat until May 25th

RE:RE:Drum beat until May 25th

RE:Drum beat until May 25th

RE:News tomorrow (surprise news)

Featured Company

Regenx Tech Corp. C.RGX

Become a member today, It's free!

Sign In

Send my password

Become a member today, It's free!

Bullboard Post History

by jimsenior

Featured Company